Brian M. Wolpin

2004–2026 年に発表

168
論文数
27,959
被引用数
84
h 指数
160
i10 指数

被引用数

Brian M. Wolpin の年別被引用数2002 年: 被引用 1 件2004 年: 被引用 5 件2005 年: 被引用 7 件2006 年: 被引用 3 件2007 年: 被引用 6 件2008 年: 被引用 20 件2009 年: 被引用 46 件2010 年: 被引用 106 件2011 年: 被引用 106 件2012 年: 被引用 83 件2013 年: 被引用 124 件2014 年: 被引用 132 件2015 年: 被引用 155 件2016 年: 被引用 206 件2017 年: 被引用 184 件2018 年: 被引用 241 件2019 年: 被引用 890 件2020 年: 被引用 1,127 件2021 年: 被引用 1,473 件2022 年: 被引用 1,414 件2023 年: 被引用 1,314 件2024 年: 被引用 2,043 件2025 年: 被引用 1,212 件2026 年: 被引用 63 件2003 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,867 件、この内訳の 25.4%中国: 引用元論文 2,413 件、この内訳の 15.9%ドイツ: 引用元論文 845 件、この内訳の 5.6%イギリス: 引用元論文 802 件、この内訳の 5.3%イタリア: 引用元論文 713 件、この内訳の 4.7%日本: 引用元論文 530 件、この内訳の 3.5%フランス: 引用元論文 498 件、この内訳の 3.3%カナダ: 引用元論文 489 件、この内訳の 3.2%スペイン: 引用元論文 425 件、この内訳の 2.8%オランダ: 引用元論文 395 件、この内訳の 2.6%オーストラリア: 引用元論文 341 件、この内訳の 2.2%韓国: 引用元論文 306 件、この内訳の 2%
0%25.4%その他 23.5%

分野

  • Medicine61.2%
  • Biochemistry, Genetics and Molecular Biology30.3%
  • Immunology and Microbiology3.3%
  • Engineering1.7%
  • Computer Science0.8%
  • Neuroscience0.6%
  • その他2.1%

トピック

  • Pancreatic and Hepatic Oncology Research9.3%
  • Ferroptosis and cancer prognosis3.9%
  • Cancer Genomics and Diagnostics3.7%
  • Cancer, Lipids, and Metabolism2.6%
  • Epigenetics and DNA Methylation2.6%
  • Cancer Cells and Metastasis2.6%
  • その他75.3%

共著者

全論文

検索で開く
  1. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Cindy Hon, Yu Chen, William C. Hahn, Mitchell P. Levesque, John G. Doench, Michael E. Berens, Alykhan F. Shamji, Paul A. Clemons, Brent R. Stockwell, Stuart L. Schreiber - Nature 2017 被引用: 2,059

  2. Acquired Resistance to KRAS G12C Inhibition in Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , J. David Lawson, Peter Olson, Piro Lito, Sai-Hong I. Ou, James G. Christensen, Pasi A. Jänne, Andrew J. Aguirre - New England Journal of Medicine 2021 被引用: 1,164

  3. Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James M. McFarland, Ewa Sicińska, Tyler Jacks, Ryan J. Sullivan, Geoffrey I. Shapiro, Thomas E. Clancy, Kimberly Perez, Douglas A. Rubinson, Kimmie Ng, James M. Cleary, Lorin Crawford, Scott R. Manalis, Jonathan A. Nowak, Brian M. Wolpin, William C. Hahn, Andrew J. Aguirre, Alex K. Shalek - Cell 2021 被引用: 614

  4. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Hans Clevers, Laura D. Wood, Ralph H. Hruban, Elizabeth D. Thompson, Andrew J. Aguirre, Brian M. Wolpin, Aaron R. Sasson, Joseph Kim, Maoxin Wu, Juan Carlos Bucobo, Peter J. Allen, Divyesh V. Sejpal, William H. Nealon, J. D. Sullivan, Jordan M. Winter, Phyllis A. Gimotty, Jean L. Grem, Dominick J. DiMaio, Jonathan M. Buscaglia, Paul M. Grandgenett, Jonathan R. Brody, Michael A. Hollingsworth, Grainne M. O’Kane, Faiyaz Notta, Edward Kim, James M. Crawford, Craig Devoe, Allyson J. Ocean, Christopher L. Wolfgang, Kenneth H. Yu, Ellen Li, Christopher R. Vakoc, Benjamin Hubert, Sandra E. Fischer, Julie M. Wilson, Richard A. Moffitt, Jennifer J. Knox, Alexander Krasnitz, Steven Gallinger, David A. Tuveson - Cancer Discovery 2018 被引用: 1,094

  5. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeanne Shen, Charles M. Vollmer, Robert A. Wolff, Brian M. Wolpin, Beth Lynn, Giby V. George - Journal of the National Comprehensive Cancer Network 2021 被引用: 1,286

  6. A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2023 被引用: 320

  7. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2020 被引用: 533

  8. Low glycaemic diets alter lipid metabolism to influence tumour growth

    著者: , , , , , , , , - Nature 2021 被引用: 308

  9. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Priya S. Hibshman, Amber M. Amparo, Connor J. Hennessey, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Jens Brodbeck, Lorenzo Tomassoni, Basil Bakir, Nicholas D. Socci, Laura E. Herring, Natalie K. Barker, Junning Wang, James M. Cleary, Brian M. Wolpin, John A. Chabot, Michael D. Kluger, Gulam A. Manji, Kenneth Y. Tsai, Miroslav Sekulic, Stephen M. Lagana, Andrea Califano, Elsa Quintana, Zhengping Wang, Jacqueline A.M. Smith, Matthew Holderfield, David Wildes, Scott W. Lowe, Michael A. Badgley, Andrew J. Aguirre, Robert H. Vonderheide, Ben Z. Stanger, Timour Baslan, Channing J. Der, Mallika Singh, Kenneth P. Olive - Nature 2024 被引用: 175

  10. Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ben Z. Stanger, Simona Cristea, Scott W. Lowe, Timour Baslan, Eliezer M. Van Allen, Joseph D. Mancias, Emily Chan, Abraham Anderson, Yuliya V. Katlinskaya, Alex K. Shalek, David S. Hong, Shubham Pant, Jill Hallin, Kenna Anderes, Peter Olson, Timothy P. Heffernan, Seema Chugh, James G. Christensen, Anirban Maitra, Brian M. Wolpin, Srivatsan Raghavan, Jonathan A. Nowak, Peter Winter, Stephanie K. Dougan, Andrew J. Aguirre - Cancer Discovery 2024 被引用: 234

  11. The Mediterranean diet, plasma metabolome, and cardiovascular disease risk

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2020 被引用: 367

  12. 652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)

    著者: , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 115

  13. Tissue of origin dictates branched-chain amino acid metabolism in mutantKras-driven cancers

    著者: , , , , , , , , , , , , , , , , - Science 2016 被引用: 585

  14. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

    著者: , , , , , , , , , , , , , , - Investigational New Drugs 2019 被引用: 182

  15. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 被引用: 180

  16. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas J. Wang, Robert E. Gerszten, Charles S. Fuchs, Matthew G. Vander Heiden, Brian M. Wolpin - Nature Medicine 2014 被引用: 662

  17. Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas

    著者: , , , , , , , , , , , , , , , , , - JAMA Oncology 2022 被引用: 281

  18. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Richard F. Dunne, Daniel T. Chang, Albert C. Koong, Aram F. Hezel, William C. Hahn, Alex K. Shalek, Andrew J. Aguirre, Jonathan A. Nowak, Brian M. Wolpin - Cancer Research 2022 被引用: 90

  19. Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2019 被引用: 226

  20. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2021 被引用: 162

  21. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 被引用: 159

  22. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarah P. Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer L. Burns, Susan Darlow - Journal of the National Comprehensive Cancer Network 2017 被引用: 1,030

  23. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Leona A. Doyle, Aaron R. Thorner, Matthew D. Ducar, Bruce M. Wollison, Angelica Laing, William C. Hahn, Matthew Meyerson, Charles S. Fuchs, Shuji Ogino, Jason L. Hornick, Aram F. Hezel, Albert C. Koong, Brian M. Wolpin - JAMA Oncology 2017 被引用: 269

  24. Lead-Time Trajectory of CA19-9 as an Anchor Marker for Pancreatic Cancer Early Detection

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2020 被引用: 201